Nintedanib 100 Bid [clinicaltrials_resource:NCT00514683/group/O4]
Patients were treated with 100mg nintedanib twice daily
group [clinicaltrials_vocabulary:group]
NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/0257503365cc46c4f05db0562736562c]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/03a8ecfa96dc6706957a65be4f3859fa]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/076dae0198365801a3f58038640db41e]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/095a006813ccd73738bd06a9f1a44f02]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/0cf889398967f0e1d3f0766d091eaa3f]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/0f06c0ab5eaaf6934afa7996c0592488]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/10bdd250647674cb72e481c115e6c0cc]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/15233dfffc861953cdf48d22ae23150d]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/17d8715c8df22f3e186b17da5527a459]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/1dc422a764e192186b32380344c0ea82]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/292226cf5f24acd6c07f0b3eb139fa71]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/2942df937d552b0ba0e2768cf839aded]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/2a198c3af8c78155857082e8cfdd1ab7]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/300929af26dedf29ee2e7cd2eae06303]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/367a615cc10ee50c7ed7cb8fb1065cd4]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/4a2bf7340f86d3f49284a4173d1bd406]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/551819b6f82dddb1209961510aded8b5]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/5a559901309ff88d003a4c89ac567faa]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/5cfcc0fcd1e905c6655b552062b2796f]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/5ff60622a7c0650c544ddf372aef838d]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/606502db9f32b0759e3198d11af38214]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/624a4352ab056bcd8aeca6fe5022b51b]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/628bdfe0c1d4de94c9779d22743d0a52]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/674d4b57f83c0d82bb4ecae14ebbe61c]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/6a585dfff82fadafc5ef138664f89799]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/6f25de064e7de54862e1b631974f85bf]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/6f3f69121832d41994080e4f7b6893e0]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/734938a2eac64d5e9163d066f4a656b7]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/7c1122a3bd2b017843a9b325eb909383]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/83d9409c9be1820b9eafd106d5f7052c]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/86c0c1903fa59ac5d0b0064388d6cd78]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/888db4ee4dd0f9df2dc12c44f9f8faeb]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/9c17a1788c21015c041da18d781e7d1b]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/9da3c9704b3f48006578fbf5336a453c]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/a344edd1098826de9edabf7bf420fbf1]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/a50ee3a50e833178b265407883b83179]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/a8dbb8f66db35f9c67683d2e9e1580e3]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/b3ade8441afa6734aac9d11dbf4edae4]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/b68bc86e86beacdf916acd4331ebf122]NCT00514683 measurement [clinicaltrials_resource:NCT00514683/measurement/b7900e67a5c81d7c11cddf2068ee4309]
group id [clinicaltrials_vocabulary:group-id]
Nintedanib 100 Bid [clinicaltrials_resource:NCT00514683/group/O4]
Patients were treated with 100mg nintedanib twice daily
Bio2RDF identifier
NCT00514683/group/O4
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:NCT00514683/group/O4
group id [clinicaltrials_vocabulary:group-id]
description
Patients were treated with 100mg nintedanib twice daily
@en
identifier
clinicaltrials_resource:NCT00514683/group/O4
title
Nintedanib 100 Bid
@en
type
label
Nintedanib 100 Bid [clinicaltrials_resource:NCT00514683/group/O4]
@en